The Universities of Liverpool and Manchester have been awarded a £1 million scheme by the MRC (Medical Research Council) to provide clinical research training in Clinical Pharmacology and Therapeutics.
The scheme was launched by the MRC as a result of the Blueprint from the Office of Life Sciences. It allows integration of expertise and technologies across the M62 and, by working with industry partners such as Astra Zeneca and GlaxoSmithkline, will provide ‘without walls’ research training. The programme is based on an established Liverpool-Manchester collaboration, the MRC Centre for Drug Safety Science, which is lead by the University and provides the management framework.
The programme focuses on three-year doctoral training for six clinical fellows divided equally between the universities of Liverpool and Manchester. The programme will utilise the combined academic strengths of the universities to focus on stratified medicines and drug safety in the areas of paediatrics, infectious diseases, and inflammation and repair.